Day: September 7, 2021

PHOENIX, Sept. 07, 2021 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (NEO:TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, will be participating at three upcoming conferences in September 2021:Beacon Cannabis Conference is being held on September 9, 2021. The Company will host institutional investors for 1×1 meetings. Echelon Cannabis Conference: Exploring Underappreciated Opportunities in U.S. Cannabis is being held on September 22, 2021. Investors can watch TILT’s CEO Gary Santo present here. Business of Cannabis Conference: New York will be held on September 29, 2021 at the Rockefeller Center in New York City. CEO Gary Santo will be speaking at this first joint event...

Dino DiMarino Departing for New Opportunity Search Process Underway to Identify Successor LEXINGTON, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) — Mimecast Limited (NASDAQ: MIME), a leading email security and cyber resilience company, today announced it has appointed Joe Mercurio Interim Chief Revenue Officer (CRO), effective October 5, 2021. This appointment follows the resignation of Chief Revenue Officer, Dino DiMarino, who will depart from the Company in early October to pursue another opportunity. Mr. DiMarino will work with Mr. Mercurio, supported by CEO Peter Bauer, CFO Rafe Brown as well as the existing global sales leadership team, to facilitate an orderly transition. Mimecast has initiated a search to identify Mr. DiMarino’s successor with the assistance of the executive search firm Daversa Partners. “I want to thank Dino...

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors. “We are pleased to welcome Iain, a world-renowned leader in rheumatology and clinical immunology, to our Board of Directors,” said Simba Gill, Ph.D., Chief Executive Officer of Evelo. “Over the course of his career, Iain has played an instrumental role in developing new treatments for inflammatory diseases, leading research efforts to understand the key cellular and molecular pathways that drive these conditions, and participating in numerous clinical trials of novel biologic agents. His breadth of expertise will be critical as we progress our product portfolio...

– Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform – – Adaptimmune will receive $150 million upfront, $150 million over the next five years in additional payments, and development, regulatory and commercial milestones payments potentially exceeding $3 billion in aggregate value, as well as royalties, across multiple programs – – The Company will host a virtual update about its allogeneic platform on Thursday, September 9 at 08:00 a.m. EDT (01:00 p.m. BST) – PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 07, 2021 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq: ADAP),...

BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences. H.C. Wainwright 23rd Annual Global Investment Conference Format: Fireside chat with analyst, Swayampakula RamakanthDate: Monday, September 13Time: 7:00 AM Eastern TimeWebcast link: Available here Cantor Virtual Global Healthcare ConferenceFormat: Fireside chat with analyst, Alethia YoungDate: Tuesday, September 28Time: 11:50 AM Eastern TimeWebcast link: Available here A live webcast of the fireside chats can be accessed by visiting the Investors...

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021. The presentation will be made available for on-demand listening beginning Monday, September 13, 2021 at 7:00 a.m. Eastern Time and may be accessed on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be made available for a period of 30 days following the event. About Baudax Bio Baudax Bio is a pharmaceutical company...

PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported that Maxine Gowen, Ph.D., has been appointed chairwoman of the board of directors for the company, effective August 31. Dr. Gowen is an accomplished biopharmaceutical executive who has deep operational and research and development experience. Dr. Gowen has been a member of Passage Bio’s board since February 2021 and currently serves on the Nominating and Corporate Governance Committee. She will continue to serve on this committee in her capacity as board chairwoman. “I am delighted that Maxine will be leading our board of directors following the unexpected passing of our former Chairman Dr. Tadataka Yamada,”...

DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix and Mike Andriole, Chief Financial and Business Officer of Chimerix, will participate in a pre-recorded fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference that will be made available on Monday, September 13, 2021 at 7:00 a.m. ET. An audio webcast of the fireside chat will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative...

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) — Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will present at two upcoming virtual investor conferences in September:H.C. Wainwright 23rd Annual Global Investment Conference. Pre-recorded fireside chat available for on-demand viewing starting on Monday, September 13 at 7:00 a.m. EDT Morgan Stanley Virtual Global Healthcare Conference. Fireside chat on Monday, September 13 at 5:00 p.m. EDTAn on-demand webcast of the H.C. Wainwright fireside chat and a live webcast of the Morgan Stanley fireside chat will be accessible through the investors...